who cares about nasdaq?, page-39

Ramses,

Thanks for the compliment. Imo, from what Ive seen lately we are already fortunate to have some quality contributors to the PRR forum.

When I first invested in PRR in 2009 it was a different story as per the following reference: click here for 2009 PRR thread example posted on OBJ forum or Post: 6266817 (obj - patience wearing thin - 01/01/2011) if the link doesn't work.
__________

Peace & Granev,

Thanks for your replies.

I missed the UNS code change so I stand corrected on that point Granev.

Although I havent researched UNS Im not convinced that a Nasdaq listing nor their relocation to the US is responsible for their decline. Imo transdermal technologies and certainly the new innovative transdermal technology trends are moving away from syringes, which primarily has always been and still remains UNSs focus.

If we look at another example and this one during the GFC:

HeartWare International ASX:HIN

Dec 3, 2008 - $0.40c
Dec 4, 2008 - $0.50c Files for NASDAQ Listing up 25%
Feb 20, 2009 $1.10c - NASDAQ listing approved up a further 120% since Dec 4 & the largest volume day in the companys history

Im not suggesting that the listing approval will be a rocket launcher but imo I remain without doubt, even with only 3% issue that US investors will lead the bio-blind Australian market.

Remember just before Christmas Martin Rogers went to the US to conduct presentations to fund managers and institutions at a Deutsche Bank Conference in Boston... then what followed soon after?

He dumped Springtree!

US investors understand the biotech sector better than the Australian market. They understand the desperate requirement for Global Pharmas to find the next multi-billion dollar block buster drugs to insulate themselves from impact the huge pending patent cliff.

Imo, its that simple. They will also quickly learn to appreciate the therapeutic similarities between Dendreons Provenge and our CVac which will further highlight the opportunity Prima offers for US investors

"With the strong demand for Prima from US investors and the strength of the US biotech and healthcare investment market Prima is extremely well positioned to be at the forefront of cancer immunotherapy development companies, and it is a market sub-sector which has enormous upside potential". ~ from the head of US Investment Bank, National Securities Corp

"Prima has received significant interest from a number of major institutional investment groups, and Primas executive director, Mr Martin Rogers, will begin discussions in North America with a number of hedge funds and other biotech focused investment funds"... from May 2009 Ann
__________

Billy,

I have only ever known two persons by the name of Billy and both with ovaries so my apologies for assuming your gender by association ;)

"This product would be great for me when they prove it for Ovarian Cancer because the doctors told me it could do wonders for liver cancer..." With my sincere respect Billy, its assuring to hear that cancer specialists in hospitals are already discussing CVac.

May the dreams of your past be the reality of your future my friend

Ovarian Cancer Awareness Month - February 2011